IDEXX Laboratories, Inc. (IDXX)
NASDAQ: IDXX · Real-Time Price · USD
568.30
-6.65 (-1.16%)
At close: Apr 28, 2026, 4:00 PM EDT
567.85
-0.45 (-0.08%)
After-hours: Apr 28, 2026, 7:55 PM EDT
IDEXX Laboratories Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for IDEXX Laboratories stock have an average target of 721.67, with a low estimate of 600 and a high estimate of 805. The average target predicts an increase of 26.99% from the current stock price of 568.30.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for IDEXX Laboratories stock from 9 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 5 | 5 | 4 | 4 | 4 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 10 | 10 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $730 → $640 | Hold | Maintains | $730 → $640 | +12.62% | Apr 28, 2026 |
| Citigroup | Citigroup | Hold Initiates $650 | Hold | Initiates | $650 | +14.38% | Apr 15, 2026 |
| Stifel | Stifel | Strong Buy Maintains $775 → $675 | Strong Buy | Maintains | $775 → $675 | +18.78% | Mar 31, 2026 |
| Piper Sandler | Piper Sandler | Hold Maintains $775 → $750 | Hold | Maintains | $775 → $750 | +31.97% | Feb 9, 2026 |
| Barclays | Barclays | Buy Maintains $850 → $800 | Buy | Maintains | $850 → $800 | +40.77% | Feb 5, 2026 |
Financial Forecast
Revenue This Year
4.77B
from 4.30B
Increased by 10.88%
Revenue Next Year
5.18B
from 4.77B
Increased by 8.59%
EPS This Year
14.81
from 13.08
Increased by 13.21%
EPS Next Year
16.72
from 14.81
Increased by 12.92%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.9B | 5.4B | ||||||
| Avg | 4.8B | 5.2B | ||||||
| Low | 4.6B | 4.9B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 14.8% | 13.9% | ||||||
| Avg | 10.9% | 8.6% | ||||||
| Low | 6.1% | 2.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 15.47 | 17.73 | ||||||
| Avg | 14.81 | 16.72 | ||||||
| Low | 13.89 | 15.54 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 18.2% | 19.8% | ||||||
| Avg | 13.2% | 12.9% | ||||||
| Low | 6.2% | 5.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.